Wereldhave Valuation
Is 0NMR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0NMR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0NMR (€14) is trading below our estimate of fair value (€14)
Significantly Below Fair Value: 0NMR is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0NMR?
Key metric: As 0NMR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 0NMR's PE Ratio? | |
|---|---|
| PE Ratio | 6.1x |
| Earnings | €101.20m |
| Market Cap | €612.42m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 9.7x |
| Enterprise Value/EBITDA | 15.9x |
| PEG Ratio | 4.3x |
Price to Earnings Ratio vs Peers
How does 0NMR's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 58.6x | ||
NRR NewRiver REIT | 95.1x | 33.0% | UK£285.2m |
CAL Capital & Regional | 69.8x | 47.8% | UK£146.5m |
SHC Shaftesbury Capital | 62.5x | 28.4% | UK£2.3b |
THRL Target Healthcare REIT | 7.1x | 3.4% | UK£519.8m |
0NMR Wereldhave | 6.1x | 1.4% | €612.4m |
Price-To-Earnings vs Peers: 0NMR is good value based on its Price-To-Earnings Ratio (6.1x) compared to the peer average (58.6x).
Price to Earnings Ratio vs Industry
How does 0NMR's PE Ratio compare vs other companies in the European Retail REITs Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 0NMR is good value based on its Price-To-Earnings Ratio (6.1x) compared to the European Retail REITs industry average (21.6x).
Price to Earnings Ratio vs Fair Ratio
What is 0NMR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 6.1x |
| Fair PE Ratio | 14.4x |
Price-To-Earnings vs Fair Ratio: 0NMR is good value based on its Price-To-Earnings Ratio (6.1x) compared to the estimated Fair Price-To-Earnings Ratio (14.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €14.00 | €16.67 +19.0% | 6.2% | €18.00 | €15.50 | n/a | 3 |
| Nov ’25 | €14.25 | €16.67 +16.9% | 6.2% | €18.00 | €15.50 | n/a | 3 |
| Oct ’25 | €14.94 | €16.17 +8.2% | 8.1% | €18.00 | €15.00 | n/a | 3 |
| Sep ’25 | €14.14 | €16.00 +13.2% | 6.8% | €17.50 | €15.00 | n/a | 3 |
| Aug ’25 | €13.81 | €16.00 +15.9% | 6.8% | €17.50 | €15.00 | n/a | 3 |
| Jul ’25 | €13.32 | €16.00 +20.1% | 6.8% | €17.50 | €15.00 | n/a | 3 |
| Jun ’25 | €13.92 | €16.00 +14.9% | 6.8% | €17.50 | €15.00 | n/a | 3 |
| May ’25 | €13.12 | €16.00 +22.0% | 6.8% | €17.50 | €15.00 | n/a | 3 |
| Apr ’25 | €14.44 | €16.00 +10.8% | 6.8% | €17.50 | €15.00 | n/a | 3 |
| Mar ’25 | €13.42 | €16.00 +19.2% | 6.8% | €17.50 | €15.00 | n/a | 3 |
| Feb ’25 | €13.66 | €16.17 +18.3% | 8.1% | €18.00 | €15.00 | n/a | 3 |
| Jan ’25 | €14.50 | €16.67 +14.9% | 10.2% | €19.00 | €15.00 | n/a | 3 |
| Dec ’24 | €15.50 | €17.67 +14.0% | 7.1% | €19.00 | €16.00 | n/a | 3 |
| Nov ’24 | €14.50 | €17.67 +21.8% | 7.1% | €19.00 | €16.00 | €14.25 | 3 |
| Oct ’24 | €15.08 | €17.67 +17.2% | 7.1% | €19.00 | €16.00 | €14.94 | 3 |
| Sep ’24 | €15.94 | €17.50 +9.8% | 6.2% | €18.50 | €16.00 | €14.14 | 3 |
| Aug ’24 | €16.14 | €17.50 +8.4% | 6.2% | €18.50 | €16.00 | €13.81 | 3 |
| Jul ’24 | €14.00 | €16.50 +17.9% | 12.1% | €18.50 | €14.50 | €13.32 | 2 |
| Jun ’24 | €13.72 | €16.50 +20.2% | 12.1% | €18.50 | €14.50 | €13.92 | 2 |
| May ’24 | €13.89 | €16.50 +18.8% | 12.1% | €18.50 | €14.50 | €13.12 | 2 |
| Apr ’24 | €14.21 | €16.50 +16.1% | 12.1% | €18.50 | €14.50 | €14.44 | 2 |
| Mar ’24 | €14.89 | €15.75 +5.8% | 7.9% | €17.00 | €14.50 | €13.42 | 2 |
| Feb ’24 | €13.86 | €14.25 +2.8% | 1.8% | €14.50 | €14.00 | €13.66 | 2 |
| Jan ’24 | €12.64 | €14.25 +12.7% | 1.8% | €14.50 | €14.00 | €14.50 | 2 |
| Dec ’23 | €13.25 | €13.83 +4.4% | 4.5% | €14.50 | €13.00 | €15.50 | 3 |
| Nov ’23 | €12.63 | €13.83 +9.5% | 4.5% | €14.50 | €13.00 | €14.50 | 3 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Xior Student Housing
€1.3b
Xior Student Housing NV is the first Belgian public regulated real estate company (RREC) specialising in the student housing segment in Belgium, the Netherlands, Spain, Portugal, Germany, Poland, Denmark and Sweden.
0RD8
€29.93
7D
-0.9%
1Y
-4.7%
Immobiliare Grande Distribuzione SIIQ
€241.1m
Immobiliare Grande Distribuzione SIIQ S.p.A.
0STP
€2.18
7D
-2.4%
1Y
-1.0%
Mercialys
€991.5m
Mercialys is one of France’s leading real estate companies.
MERYP
€10.54
7D
1.1%
1Y
n/a